Evidence map›Paper›PMID 37138478›Full record

ReviewCNS & neurological disorders drug targets2024

Emerging Nanotechnology for the Treatment of Alzheimer's Disease.

Aditya Singh, Vaseem Ahamad Ansari, Tarique Mahmood, Farogh Ahsan, Rufaida Wasim, Shubhrat Maheshwari, Mohammad Shariq, Saba Parveen, Arshiya Shamim

Abstract readReview
PubMed Publisher
In one paragraph

Review in CNS & neurological disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Aditya SinghDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.
Vaseem Ahamad AnsariDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.ORCID 0000-0002-8896-5063
Tarique MahmoodDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.
Farogh AhsanDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.
Rufaida WasimDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.
Shubhrat MaheshwariFaculty of Pharmaceutical Sciences Rama University Mandhana, Bithoor Road, Kanpur, Uttar Pradesh-209217, India.
Mohammad ShariqDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.
Saba ParveenDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.
Arshiya ShamimDepartment of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow, UP-226026, India.
Integral University · INRama University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology is a great choice for medical research, and the green synthesis approach is a novel and better way to synthesize nanoparticles. Biological sources are cost-effective, environmentally friendly, and allow large-scale production of nanoparticles. Naturally obtained 3 β-hydroxy-urs- 12-en-28-oic acids reported for neuroprotective and dendritic structure are reported as solubility enhancers. Plants are free from toxic substances and act as natural capping agents. In this review, the pharmacological properties of ursolic acid (UA) and the structural properties of the dendritic structure are discussed. UA acid appears to have negligible toxicity and immunogenicity, as well as favorable biodistribution, according to the current study, and the dendritic structure improves drug solubility, prevents drug degradation, increases circulation time, and potentially targets by using different pathways with different routes of administration. Nanotechnology is a field in which materials are synthesized at the nanoscale. Nanotechnology could be the next frontier of humankind's technological advancement. Richard Feynman first used the term 'Nanotechnology' in his lecture, "There is Plenty of Room at the Bottom", on 29th December, 1959, and since then, interest has increased in the research on nanoparticles. Nanotechnology is capable of helping humanity by solving major challenges, particularly in neurological disorders like Alzheimer's disease (AD), the most prevalent type, which may account for 60-70% of cases. Other significant forms of dementia include vascular dementia, dementia with Lewy bodies (abnormal protein aggregates that form inside nerve cells), and a number of illnesses that exacerbate frontotemporal dementia. Dementia is an acquired loss of cognition in several cognitive domains that are severe enough to interfere with social or professional functioning. However, dementia frequently co-occurs with other neuropathologies, typically AD with cerebrovascular dysfunction. Clinical presentations show that neurodegenerative diseases are often incurable because patients permanently lose some neurons. A growing body of research suggests that they also advance our knowledge of the processes that are probably crucial for maintaining the health and functionality of the brain. Serious neurological impairment and neuronal death are the main features of neurodegenerative illnesses, which are also extremely crippling ailments. The most prevalent neurodegenerative disorders cause cognitive impairment and dementia, and as average life expectancy rises globally, their effects become more noticeable.

Indexed as

Alzheimer DiseaseNanoparticlesNanotechnologyAnimalsDrug Delivery SystemsHumansNeuroprotective AgentsTriterpenesUrsolic AcidNeuroprotective AgentsTriterpenesUrsolic AcidAlzheimer's diseasebioavailabilitynanoparticle.nanotechnologyneurodegenerativeUrsolic acid

Identifiers

PMID37138478
OpenAlexW4368356746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.